Assignee
INTELLIA THERAPEUTICS INC
US·12 granted patents·61 pending applications·18 citations·filing 2017–2025
Top patents by PatentIndex Score
73 records- 0193US11479767B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2019·Granted Oct 25, 2022·12 cites·27 claims
- 0289US11795460B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·24 claims
- 0388US11673911B2Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·2 cites·22 claims
- 0485US2025059532A1Modified Guide RNAsINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0583US11549107B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2019·Granted Jan 10, 2023·2 cites·21 claims
- 0682US2026015611A1Modified Guide RNAsINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0782US2026022358A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0881US2025207130A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0980US12391722B2Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·23 claims
- 1079US12173284B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·0 cites·31 claims
- 1179US2025346625A1Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)INTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1277US11965165B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·21 claims
- 1377US2024018496A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1476US11697806B2Polynucleotides, compositions, and methods for genome editingINTELLIA THERAPEUTICS INC·Filed 2020·Granted Jul 11, 2023·1 cites·26 claims
- 1574US2023076357A1Methods and Compositions for Directed Genome EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1673US12460205B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·18 claims
- 1772US2023295587A1Compositions and Methods for Kallikrein (KLKB1) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1871US2024301377A1Polynucleotides, Compositions, and Methods for Genome EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1971US2025255940A1Compositions and methods for expressing factor ixINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2071US2024124897A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2170US12480109B2Compositions and methods for kallikrein (KLKB1) gene editingINTELLIA THERAPEUTICS INC·Filed 2025·Granted Nov 25, 2025·0 cites·27 claims
- 2270US2025262302A1Compositions and Methods for Reducing MHC Class I in a CellINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2369US2025276017A1Compositions and Methods for Genomic EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2467US2025276090A1Methods and Compositions for Genetically Modifying a CellINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2566US2023203480A1Lipid nanoparticle formulations for crispr/cas componentsINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2665US2024299583A1Modified Guide RNAs for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2765US2025074866A1Modified amine lipidsINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2865US2024139323A1Compositions and Methods for Genetically Modifying CIITA in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2965US2024002820A1Polynucleotides, Compositions, and Methods for Genome Editing Involving DeaminationINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3064US2026043026A1Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)INTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3164US2024076636A1Polynucleotides, Compositions, and Methods for Genome EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3264US2024016934A1Compositions and Methods for Reducing MHC Class II in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3364US2024150761A1Modified Guide RNAs Comprising an Internal Linker for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3464US2026007772A1Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3563US2020248180A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3663US2026035697A1Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3763US2025268940A1Chimeric antigen receptor compositions and usesINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3862US12214023B2Compositions and methods for expressing factor IXINTELLIA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·0 cites·16 claims
- 3962US2023044994A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4062US2024024478A1Compositions and Methods for Reducing HLA-A in a CellINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4162US2025302874A1Cd38 compositions and methods for immunotherapyINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4261US2025025580A1Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor FourINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4359US2024316100A1Engineered t cellsINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4457US2021222173A1Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4557US2022372483A1Modified Guide RNAs for Gene EditingINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4656US12077483B2Modified amine lipidsINTELLIA THERAPEUTICS INC·Filed 2019·Granted Sep 3, 2024·0 cites·21 claims
- 4756US2022354967A1Compositions and methods for transgene expression from an albumin locusINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4856US2020270617A1Compositions and methods for transgene expression from an albumin locusINTELLIA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4956US2025269062A1Methods for in vivo editing of a liver geneINTELLIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5055US2023035659A1Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →